The Queensland Government has rejected calls to reconsider its restrictions on puberty-suppressing medication for young transgender and gender-diverse people, following new interim medical advice released by Australia's National Health and Medical Research Council (NHMRC).

The issue became a major topic of discussion on 18 November 2026 after parents and advocacy organisations called on the state government to review its existing policy. The national health advisory body's recommendations have reopened debate about how young people should access specialist healthcare across Australia.

The NHMRC recently released interim advice following a review of available medical evidence. Its recommendations state that puberty-suppressing medication can be considered for certain young people under 18 following an individual clinical assessment and shared decision-making involving the young person, their parents or carers and treating clinicians.

The advisory body made a conditional recommendation rather than suggesting that the medication should automatically be prescribed to every patient. It emphasised that treatment decisions must consider individual circumstances, potential benefits, possible risks and the available medical evidence.

However, Queensland Health Minister Tim Nicholls said the state government's position would remain unchanged. Queensland previously introduced restrictions on new prescriptions of puberty blockers for young people with gender dysphoria in the public healthcare system. The government has indicated that these restrictions will continue until at least 2031.

The Queensland Government said its position was based on an earlier independent review examining the available evidence surrounding puberty blockers and hormone treatments. The state has maintained that the health, safety and wellbeing of young Queenslanders remain its priority.

The national recommendations have also attracted attention from parents who believe that the existing restrictions should be reconsidered. Some families have expressed concerns about accessing appropriate specialist services and the impact that delays in healthcare decisions can have on young people.

The debate has highlighted differences between national medical advice and state-level healthcare policies. Although the NHMRC provides guidance based on its review of scientific evidence, its interim recommendations are not legally binding on individual state governments.

This means Queensland can continue implementing its existing restrictions even when national health experts recommend that the treatment remain a clinical option in certain circumstances.

The federal government has encouraged states and territories to carefully consider the NHMRC's advice. However, decisions about the delivery of public healthcare services remain the responsibility of individual jurisdictions.

The Northern Territory has also maintained restrictions on the treatment, demonstrating that the issue extends beyond Queensland.

The NHMRC is expected to continue developing comprehensive national clinical guidelines for the care of transgender and gender-diverse people under 18. These guidelines are scheduled for release in 2028 and are intended to provide a more consistent framework for healthcare professionals across Australia.

For now, Queensland's existing policy remains in place, and no immediate change to public healthcare access has been announced.

The discussion is expected to continue as medical organisations, families, policymakers and advocacy groups examine the evidence and consider how healthcare decisions should be made in the future.